GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Total Assets

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Total Assets : $2,163.2 Mil (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Total Assets?

Taro Pharmaceutical Industries's Total Assets for the quarter that ended in Dec. 2023 was $2,163.2 Mil.

During the past 3 years, the average Total Assets Growth Rate was 1.40% per year. During the past 5 years, the average Total Assets Growth Rate was 5.80% per year. During the past 10 years, the average Total Assets Growth Rate was 8.90% per year.

During the past 13 years, Taro Pharmaceutical Industries's highest 3-Year average Total Assets Growth Rate was 59.30%. The lowest was -9.90%. And the median was 13.90%.

Total Assets is connected with ROA %. Taro Pharmaceutical Industries's annualized ROA % for the quarter that ended in Dec. 2023 was 3.77%. Total Assets is also linked to Revenue through Asset Turnover. Taro Pharmaceutical Industries's Asset Turnover for the quarter that ended in Dec. 2023 was 0.07.


Taro Pharmaceutical Industries Total Assets Historical Data

The historical data trend for Taro Pharmaceutical Industries's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Total Assets Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,135.33 2,341.25 2,406.87 2,176.36 2,135.51

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2,135.51 2,135.05 2,119.47 2,163.18

Taro Pharmaceutical Industries Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Taro Pharmaceutical Industries's Total Assets for the fiscal year that ended in Mar. 2023 is calculated as

Total Assets=Total Equity (A: Mar. 2023 )+Total Liabilities (A: Mar. 2023 )
=1730.859+404.654
=2,135.5

Taro Pharmaceutical Industries's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=1779.093+384.086
=2,163.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taro Pharmaceutical Industries  (NYSE:TARO) Total Assets Explanation

Total Assets is connected with ROA %.

Taro Pharmaceutical Industries's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=80.832/( (2119.473+2163.179)/ 2 )
=80.832/2141.326
=3.77 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Taro Pharmaceutical Industries's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=157.145/( (2119.473+2163.179)/ 2 )
=157.145/2141.326
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Taro Pharmaceutical Industries Total Assets Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro to Announce Third Quarter Results on January 27, 2021

By Business Wire Business Wire 01-21-2021

Taro Achieves Global Resolution of DOJ Antitrust Investigations

By Business Wire Business Wire 07-24-2020

Taro to Announce First Quarter Results on July 27, 2021

By Business Wire Business Wire 07-21-2021

Taro to Release Third Quarter Results on January 24, 2023

By Business Wire Business Wire 01-19-2023

Taro to Announce Second Quarter Results on October 28, 2020

By Business Wire Business Wire 10-22-2020

Taro to Announce First Quarter Results on July 29, 2020

By Business Wire Business Wire 07-22-2020